Barclays’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-407,300
| Closed | -$32.5M | – | 5431 |
|
|
2024
Q4 | $32.5M | Buy |
407,300
+35,000
| +9% | +$3.03M | 0.01% | 851 |
|
|
2024
Q3 | $33.5M | Sell |
372,300
-718,600
| -66% | -$60.5M | 0.01% | 821 |
|
|
2024
Q2 | $85.9M | Buy |
+1,090,900
| New | +$89.4M | 0.03% | 440 |
|
|
2024
Q1 | – | Sell |
-98,600
| Closed | -$8.12M | – | 5266 |
|
|
2023
Q4 | $8.12M | Buy |
+98,600
| New | +$7.51M | ﹤0.01% | 1683 |
|
|
2022
Q1 | – | Sell |
-106,400
| Closed | -$11M | – | 5361 |
|
|
2021
Q4 | $11M | Buy |
+106,400
| New | +$12.3M | ﹤0.01% | 1217 |
|
|
2021
Q1 | – | Sell |
-314,000
| Closed | -$36.8M | – | 5005 |
|
|
2020
Q4 | $36.8M | Buy |
314,000
+246,500
| +365% | +$27.1M | 0.02% | 553 |
|
|
2020
Q3 | $7.01M | Sell |
67,500
-2,300
| -3% | -$231K | ﹤0.01% | 1197 |
|
|
2020
Q2 | $6.4M | Sell |
69,800
-255,700
| -79% | -$24.5M | ﹤0.01% | 1197 |
|
|
2020
Q1 | $29.4M | Sell |
325,500
-106,000
| -25% | -$11.3M | 0.02% | 490 |
|
|
2019
Q4 | $49M | Buy |
431,500
+355,800
| +470% | +$39M | 0.03% | 520 |
|
|
2019
Q3 | $8.22M | Sell |
75,700
-85,700
| -53% | -$8.94M | 0.01% | 1441 |
|
|
2019
Q2 | $15.7M | Buy |
161,400
+52,800
| +49% | +$4.82M | 0.01% | 1071 |
|
|
2019
Q1 | $9.89M | Sell |
108,600
-373,600
| -77% | -$33.4M | 0.01% | 1232 |
|
|
2018
Q4 | $43.9M | Buy |
482,200
+362,300
| +302% | +$33.9M | 0.03% | 423 |
|
|
2018
Q3 | $11.8M | Sell |
119,900
-138,800
| -54% | -$12.8M | 0.01% | 1169 |
|
|
2018
Q2 | $22.1M | Buy |
258,700
+31,900
| +14% | +$2.66M | 0.02% | 742 |
|
|
2018
Q1 | $18.2M | Sell |
226,800
-302,500
| -57% | -$25M | 0.01% | 893 |
|
|
2017
Q4 | $42.7M | Buy |
529,300
+111,300
| +27% | +$8.91M | 0.03% | 472 |
|
|
2017
Q3 | $32.5M | Buy |
418,000
+30,600
| +8% | +$2.54M | 0.03% | 467 |
|
|
2017
Q2 | $34.4M | Sell |
387,400
-52,400
| -12% | -$4.42M | 0.04% | 394 |
|
|
2017
Q1 | $35.4M | Buy |
439,800
+141,420
| +47% | +$11M | 0.04% | 347 |
|
|
2016
Q4 | $21.3M | Buy |
298,380
+100,410
| +51% | +$7.89M | 0.02% | 567 |
|
|
2016
Q3 | $17.1M | Sell |
197,970
-91,375
| -32% | -$7.96M | 0.02% | 615 |
|
|
2016
Q2 | $25.1M | Buy |
289,345
+109,500
| +61% | +$8.86M | 0.03% | 428 |
|
|
2016
Q1 | $13.5M | Buy |
179,845
+21,445
| +14% | +$1.62M | 0.02% | 629 |
|
|
2015
Q4 | $12M | Buy |
158,400
+52,925
| +50% | +$3.98M | 0.01% | 799 |
|
|
2015
Q3 | $6.96M | Sell |
105,475
-15,625
| -13% | -$1.15M | 0.01% | 1156 |
|
|
2015
Q2 | $8.96M | Sell |
121,100
-139,545
| -54% | -$10.7M | 0.01% | 1104 |
|
|
2015
Q1 | $20.1M | Sell |
260,645
-244,555
| -48% | -$18.5M | 0.02% | 677 |
|
|
2014
Q4 | $36.4M | Buy |
505,200
+405,900
| +409% | +$28.2M | 0.04% | 474 |
|
|
2014
Q3 | $6.06M | Sell |
99,300
-163,300
| -62% | -$10.4M | 0.01% | 1601 |
|
|
2014
Q2 | $16.5M | Buy |
262,600
+116,400
| +80% | +$7.07M | 0.02% | 807 |
|
|
2014
Q1 | $8.92M | Sell |
146,200
-7,900
| -5% | -$460K | 0.01% | 1233 |
|
|
2013
Q4 | $8.78M | Sell |
154,100
-77,900
| -34% | -$4.42M | 0.01% | 1353 |
|
|
2013
Q3 | $12.3M | Sell |
232,000
-8,300
| -3% | -$447K | 0.01% | 994 |
|
|
2013
Q2 | $12.4M | Buy |
+240,300
| New | +$11.9M | 0.02% | 927 |
|
Other funds holding MDT
VCM
VPM
Barclays's MDT Position: Q1 2026 in Review
Barclays increased its Medtronic (MDT) stake by 23% in Q1 2026, buying an estimated $49.3M and bringing the position to 2,755,141 shares worth $239M. The position accounts for 0.06% of the portfolio, ranked #251.
Barclays first reported a position in MDT in Q2 2013 and has held it in 52 quarters since. The position peaked at $904M in Q2 2022. 2,231 funds tracked by Wall St. Rank hold MDT as of Q1 2026.
- Barclays held 2,755,141 shares of Medtronic worth $239M as of Q1 2026.
- Barclays bought 514,177 Medtronic shares in Q1 2026, an estimated $49.3M.
- Medtronic made up 0.06% of Barclays's portfolio in Q1 2026, its #251 holding.
- Barclays first reported a position in Medtronic in Q2 2013 and has held it in 52 quarters since.
- Barclays's Medtronic position peaked at $904M in Q2 2022.
- 2,231 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.